3BNC117-LS

3BNC117-LS First-in-Human Phase 1 Study

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo during primary HIV-1 infection to study the impact on post-treatment HIV control

The RIO Trial: A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary or Early stage HIV Infection on viral control off ART

Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)